The suppression of human prostate tumor growth mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel

Cancer Research

Volumn 60, Issue 15, 2000, Pages 4146-4151

  Jackson, J K ^a   Gleave, M E ^a   Yago, V ^a   Beraldi, E ^a   Hunter, W L ^a   Burt, H M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; LACTONE; MACROGOL DERIVATIVE; PACLITAXEL; POLYLACTIC ACID; PROSTATE SPECIFIC ANTIGEN;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CASTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG IMPLANT; DRUG RELEASE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PASTE; PRIORITY JOURNAL; PROSTATE TUMOR; SKIN ULCER; SLOW RELEASE FORMULATION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; GROWTH INHIBITORS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OINTMENTS; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033887006     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. The prostate: An increasing medical problem
2. Introduction: Prostate cancer
3. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers
4. Temporal trends in prostate cancer rates in the Pacific
5. Ability of serum prostate specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer
6. Results of conservative management of clinically localized prostate cancer
7. Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines
8. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
9. Effects of microtubule inhibitors Taxol, vinblastine and estramustine on the growth and p53 gene expression in hormone independent human prostatic JCA-1 cells
10. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastasis
11. Release of Taxol from poly(ε-caprolactone) pastes: Effect of water soluble additives
12. Prostate cancer therapy strategies based on tumor-specific biological principles: Future directions
13. Pharmacology and toxicology of Chremophor EL diluent
14. Complement activation by Chremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
15. Development of a polymeric surgical paste formulation for Taxol.
16. Development of a biodegradable polymeric paste formulation for Taxol: An in vitro and in vivo study
17. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors
18. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice
19. The antineoplastic ether lipid s-phosphonate induces apoptosis in human leukemic cells and exhibits antiangiogenic and apoptotic activity on the chorioallantoic membrane of the chick embryo
20. Acceleration of human prostate cancer in vivo by factors produced by prostate and bione fibroblasts
21. Prevalence of latent prostate carcinoma in two US populations
22. Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels
23. The efficacy and complications of salvage cryotherapy of the prostate
24. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
25. Paclitaxel: A review of its pharmacodynamic and pharmokinetic properties and theraputic potential in the treatment of cancer
26. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer
27. Inhibition of prostate cancer growth by estramustine and etoposide
28. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
29. Promotion of microtubule assembly in vitro by Taxol.
30. Interstitial Taxol delivered from a biodegradable polymer implant against experimental malignant glioma
31. A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice
32. Risk of venous access device wound complications in patients undergoing paclitaxel chemotherapy for gynecolgic malignancies
33. The effect of intermittent-release intraperitoneal chemotherapy on wound healing